Sign inJoin waitlistJoin the waitlist

Robert Mutter

Chair for Research, Department of Radiation Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Department of Radiation Oncology · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Radiation Oncology
Memorial Sloan Kettering Cancer Center
2008–2012
Internal Medicine University of Tennessee
2007–2008
Vanderbilt University School of Medicine
2003–2007

Research

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
Molecular Cell · 2019 · 225 citations
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling
Journal of Biological Chemistry · 2006 · 158 citations
Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium…
BMJ Open · 2019 · 107 citations

Sean Park
37 papers
Kimberly Corbin
32 papers
Judy Boughey
23 papers · 5 as a fellow
Kathryn Ruddy
18 papers
Tina Hieken
18 papers
Dean Shumway
17 papers
Elizabeth Yan
12 papers
Krishan Jethwa
11 papers · 8 as a resident
Jake Kloeber
10 papers
Arslan Afzal
8 papers · 4 as a resident
RG
Robert Gao
8 papers · 6 as a resident
Brad Stish
7 papers · 1 as a resident

Grants

ADAR1 Promotes Okazaki Fragment Maturation and Is a Target for Breast Cancer Therapy
National Cancer Institute · R01
Contact PI · $589.8K · Mayo Clinic Rochester
2026–2031
ATR: Targeting Mechanical Stress Induced EMT and Immune Suppression in Triple Negative Breast Cancer
National Cancer Institute · R01
Contact PI · $1.5M · Mayo Clinic Rochester
2023–2028
PD-L1 Intracellular RNA Binding Function Regulates Immune Suppression
National Cancer Institute · R01
Contact PI · $1.8M · Mayo Clinic Rochester
2021–2026

Clinical trials

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2020–2027
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer
Principal investigator · Active not recruiting
Mayo Clinic
2019–2028
A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation
Principal investigator · Completed · Phase 2
Mayo Clinic
2016–2023
A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca
Principal investigator · Completed · Phase 2
Mayo Clinic
2015–2022